Expect a Limited Role for Zurzuvae for Postpartum Depression
February 2024
New Rx zuranolone (Zurzuvae) will be the first ORAL med approved for treatment of postpartum depression.
Think of it as similar to IV brexanolone (Zulresso).
Both mimic the hormone allopregnanolone, which interacts with GABA receptors. This hormone abruptly dips around childbirth...possibly leading to major depression.
Get concise advice on drug therapy, plus unlimited access to CE
Pharmacist's Letter membership benefits include:
- 12 issues every year — what you need to know and do, right now
- Quick, practical reference charts and tools
- Comprehensive CE library to meet license renewal and state requirements
- Multiple course formats including live webinars, podcasts, and CE-in-the-Letter to match your learning style
- Plus much more!
Choose the right tier for your needs today.
Already a subscriber? Log in
Volume pricing available. Get a quote